BEGIN:VCALENDAR VERSION:2.0 PRODID:-//wp-events-plugin.com//7.2.3.1//EN BEGIN:VEVENT UID:432@biocityturku.fi DTSTART;TZID=Europe/Helsinki:20190228T120000 DTEND;TZID=Europe/Helsinki:20190228T130000 DTSTAMP:20231013T063052Z URL:https://biocityturku.fi/events/frontiers-of-science-precision-medicine -and-k-ras-mutant-cancers/ SUMMARY:Frontiers of Science: Precision Medicine and K-RAS Mutant Cancers DESCRIPTION:Professor Mariano Barbacid\, Spanish National Cancer Research C enter\, Madrid\, Spain\n\nHost: Jukka Westermarck (jukka.westermarck@utu.f i)\n\nWelcome to listen to Dr. Mariano Barbacid who is real legend of mol ecular cancer biology. His work not only led to the isolation of the first human cancer gene\, H-RAS\, but also identification of the first mutation associated with the development of human cancer. He also has made fundame ntal discoveries related to cell cycle regulation by CDKs and Cyclins\n\nD r. Barbacid was born in Madrid in 1949. He was awarded his Ph.D. from the Universidad Complutense in 1974. From 1974 to 1978 he trained as a postdoc toral fellow at the National Cancer Institute (NCI)\, Bethesda\, Maryland\ , USA. In 1978 he started his own group to work on the molecular biology o f human tumors. In 1984\, he moved to the NCI-Frederick\, Maryland as Head of the Developmental Oncology Section and in 1988\, he joined the Bristol Myers-Squibb Pharmaceutical Research Institute in Princeton\, New Jersey where he became Vice President\, Oncology Drug Discovery. In 1998\, he ret urned to his native Madrid to create and direct the Spanish National Cance r Research Center (CNIO). He stepped down as Director in June 2011 to conc entrate on his own research that currently focuses on the design of new an imal models of cancer and on the identification and validation of molecula r targets with potential therapeutic value.\nThe relevance of his work has been recognized by many domestic and international awards. To date\, Dr. Barbacid has authored 267 publications and has Hirsch "h" factor of 96.\n\ nSelected recent publications\nRAF inhibitor PLX8394 selectively disrupts BRAF dimers and RAS-independent BRAF-mutant-driven signaling. Nat Med. 201 9 Feb\;25(2):284-291.\n\nAfatinib restrains K-RAS-driven lung tumorigenesi s. Sci Transl Med. 2018 Jun 20\;10(446).\n\nc-RAF Ablation Induces Regress ion of Advanced Kras/Trp53 Mutant Lung Adenocarcinomas by a Mechanism Inde pendent of MAPK Signaling. Cancer Cell. 2018 Feb 12\;33(2):217-228.\n\nSaa 3 is a key mediator of the protumorigenic properties of cancer-associated fibroblasts in pancreatic tumors. Proc Natl Acad Sci U S A. 2018 Feb 6\;11 5(6)\n\nInactivation of Capicua in adult mice causes T-cell lymphoblastic lymphoma. Genes Dev. 2017 Jul 15\;31(14):1456-1468.\n\nA Braf kinase-inact ive mutant induces lung adenocarcinoma.Nature. 2017 Aug 10\;548(7666):239- 243.\n\nTumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS. Nature. 2017 Aug 10\;548(7666):234-238\n\n \; CATEGORIES:BiocityTurku events LOCATION:#_LOCATIONNAME\, #_LOCATIONFULLLINE\, #_LOCATIONCOUNTRY X-APPLE-STRUCTURED-LOCATION;VALUE=URI;X-ADDRESS=#_LOCATIONFULLLINE\, #_LOCA TIONCOUNTRY;X-APPLE-RADIUS=100;X-TITLE=#_LOCATIONNAME:geo:0,0 END:VEVENT BEGIN:VTIMEZONE TZID:Europe/Helsinki X-LIC-LOCATION:Europe/Helsinki BEGIN:STANDARD DTSTART:20181028T030000 TZOFFSETFROM:+0300 TZOFFSETTO:+0200 TZNAME:EET END:STANDARD END:VTIMEZONE END:VCALENDAR